Description:
HBV infection prevalence is increased in persons with HIV and adversely impacts their health. While most first-line antiretroviral regimens containing tenofovir provide de facto HBV treatment (or prevention), the use of long-acting injectable or other tenofovir-sparing HIV treatment regimens have increased the need for HIV providers to be familiar with HBV screening, prevention, and treatment principles. This presentation provides an overview of management issues related to HBV, focusing on persons with HIV. Attendees will also be introduced to ongoing research on novel therapeutics for HBV and the concept of HBV “cure”.
Speaker:
David L. Wyles, MD
Professor of Medicine
University of Colorado
Chief of Infectious Diseases
Denver Health Medical Center
Denver, CO